Compare Adecoagro SA (AGRO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adecoagro SA vs Recursion Pharmaceuticals Inc — how do they compare? Adecoagro SA trades at $9.47 (market cap $1.39B), while Recursion Pharmaceuticals Inc trades at $3.33 (market cap $1.78B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap, and Adecoagro SA pays a 3.07% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AGRO | RXRX | |
|---|---|---|
Market Cap | $1.39B | $1.78B |
Sector | Technology | Health |
52-Week High | $15.25 | $6.79 |
52-Week Low | $7.13 | $2.84 |
Enterprise Value | $3.43B | $1.30B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.45, up 0.96% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported negative net income of -$8.35M for 2025 despite $1.43B revenue, though 2026 projections show potential profitability improvement. Recent acquisition of Caarapó Mill expands operational footprint while analyst consensus leans neutral with 50% hold ratings.
Outlook remains cautious with elevated P/E ratio of 536.67 offset by attractive P/B of 0.79. Key risks include commodity volatility and integration challenges from recent acquisitions. The stock presents value opportunity if 2026 profitability targets are achieved, but requires careful monitoring of earnings trajectory.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
